Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 4, 1996, Pages 979-982

  Jacolot, Anne ^a   Tod, Michel ^a   Petitjean, Olivier ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; CEFDINIR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; QUINAPRIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; INTRAVENOUS DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; CEPHALOSPORINS; DRUG INTERACTIONS; HALF-LIFE; ISOQUINOLINES; MALE; RATS; RATS, WISTAR; TETRAHYDROISOQUINOLINES;

EID: 0029867519     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.4.979     Document Type: Article

References (14)

1. Bins, W. J., and H. Mattie. 1988. Saturation of the tubular excretion of β-lactam antibiotics. Br. J. Clin. Pharmacol. 25:41-50.
2. 14C, a potent ACE inhibitor, in laboratory animals. Pharmacologist 25:108.
3. Bowers, W. F., S. Fulton, and J. Thompson. 1984. Ultrafiltration versus equilibrium dialysis for determination of free fraction. Clin. Pharmacokinet 9(Suppl 1):49-60
4. Drummer, O. H., J. Thompson, R. Hooper, and B. Jarrott. 1985 Effect of probenecid on the disposition of captopril and captopril dimer in the rat Biochem. Pharmacol. 34:3347-3351.
5. Granero, L., M. J. Gimeno, F. Torres-Molina, J. Chesajimenez, and J. E. Perris. 1994. Studies on the renal excretion mechanisms of cefadroxil. Drug Metab. Dispos. 22:447-450.
6. Kaplan, H. R., D. G. Taylor, S. C. Olson, and L. K. Andrews. 1989. Quinapril - a preclinical review of the pharmacology, pharmacokinetics and toxicology. Angiology 40:335-350.
7. Lin, J., I. Chen, E. Ulm, and E. Druggan. 1988. Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. Drug Metab. Dispos. 16:392-396.
8. éme Série des Actualités en Pharmacie et Biologie Clinique. Ed. Peteers, Paris, France.
9. Rowland, M., and T. N. Tozer. 1989. In clinical pharmacokinetics: concepts and application, 2nd ed , p. 162. Lea & Febiger, Philadelphia.
10. Sakomoto, H., T. Hirose, S. Nakamoto, F. Shibayama, H. Kikuchi, and Y. Mine. 1988. Pharmacokinetics of FK482, a new orally active cephalosporin. in animals. J. Antibiot. (Tokyo) XLI:1896-1905.
11. Singhvi, S. M., K. J. Kripalani, A. V. Dean, G. R. Keim, J. S. Kulesza, F. S. Meeker, J. J. Shaw, and B. H. Migdalof. 1981. Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet J. Pharm. Sci. 70:885-888.
12. Van Ginneken, C. A. M., and F. G. M. Russel. 1989. Saturable pharmacokinetics in the renal excretion of drugs. Clin. Pharmacokinet. 16:38-54.
13. Vertes, V., and R. Haynie. 1992. Comparative pharmacokinetics of captopril. enalapril and quinapril. Am. J. Cardiol. 69:8C-16C.
14. Wadworth, A. N., and R. N. Brogden. 1991. Quinapril. a review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders Drugs 41:378-399.